Nurix Therapeutics Shows Positive Progress and Financial Stability in Q2 2025

Nurix Therapeutics presented updated data for bexobrutideg at EHA2025 and ICML-18, showing positive responses in patients with CLL and WM. Sanofi extended its collaboration for STAT6 to target type 2 inflammatory diseases with a $15M license fee. FDA cleared IND for IRAK4 degrader GS-6791/NX-0479. Nurix has $485.8M in cash and marketable securities.

Nurix reported financial results for Q2 2025, highlighting progress across clinical programs and collaborations. Arthur Sands, CEO, mentioned important milestones achieved, including Sanofi’s extension of the STAT6 program license and FDA clearance for IRAK4 degrader GS-6791/NX-0479 in collaboration with Gilead. Bexobrutideg data showed deep and durable responses in CLL patients.

Nurix presented positive preclinical data at AACR, showcasing the potential of its degraders targeting BTK, BRAF, and Aurora A kinase. The DEL-AI platform demonstrated the ability to identify novel binders for therapeutically relevant proteins. EMA granted Orphan Drug Designation to bexobrutideg for lymphoplasmacytic lymphoma.

Upcoming program highlights include pivotal trials for bexobrutideg in CLL and future updates on zelebrudomide and NX-1607. Nurix’s pipeline advancements with Gilead, Sanofi, and Pfizer continue. Financially, revenue for Q2 2025 was $44.1M, with $485.8M in cash and securities. Loss from operations was $48.3M.

Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on protein degradation medicines for cancer and inflammatory diseases. The company’s pipeline includes degraders of BTK and CBL-B, with collaborations with Gilead, Sanofi, and Pfizer. Nurix aims to bring innovative treatments to patients and advance the science of targeted protein degradation.

Read more at GlobeNewswire: Nurix Therapeutics Reports Second Quarter 2025 Financial